Your session is about to expire
← Back to Search
Repetitive Transcranial Magnetic Stimulation Device
MagPro X100/R30 stimulator equipped with the B70 fluid-cooled coil for Major Depressive Disorder
N/A
Recruiting
Led By Alisson Trevizol, MD
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, last day of treatment (day 5, after the final treatment) and 4 weeks post treatment
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new treatment for older adults with depression that hasn't improved with other treatments. The treatment uses magnetic pulses aimed at improving mood and reducing depression symptoms.
Eligible Conditions
- Major Depressive Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, last day of treatment (day 5, after the final treatment) and 4 weeks post treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, last day of treatment (day 5, after the final treatment) and 4 weeks post treatment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in Montgomery-Asberg Depression Rating Scale (MADRS) score
Secondary study objectives
Changes in 17 Item Hamilton Rating Scale for Depression (HDRS-17)
Changes in Beck Depression Inventory (BDI-II)
Changes in Beck Suicide Scale for Suicide Ideation (BSS)
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Active rTMS treatmentExperimental Treatment1 Intervention
Patients will receive accelerated TBS
Find a Location
Who is running the clinical trial?
Centre for Addiction and Mental HealthLead Sponsor
371 Previous Clinical Trials
83,255 Total Patients Enrolled
Alisson Trevizol, MDPrincipal InvestigatorCAMH
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have tried taking an antidepressant before but it did not work or you could not tolerate it.You are currently having thoughts of hurting yourself or ending your life.You have had a problem with drugs or alcohol in the past 3 months.You are ≥60 years old.You are an outpatient.You currently experience symptoms of a mental illness that affects your thinking and perception.You have signs of memory loss or confusion, as determined by a simple test.You have tried electroconvulsive therapy (ECT) for your depression, but it did not work.You are currently receiving rTMS treatment, but if you have received rTMS in the past, you may still be eligible.You have a working implanted electronic device like a defibrillator.You are taking more than 2 mg of lorazepam (or a similar medication) every day, or any dose of a medication used to treat seizures.You have a history of seizures or had a seizure caused by a problem inside your brain.You have a score of at least 18 on the Montgomery-Asberg Depression Rating Scale (MADRS).You have been diagnosed with a personality disorder that is the main cause of more problems than major depressive disorder (MDD).You have been diagnosed with bipolar disorder or a serious mental illness involving psychosis.You have been diagnosed with certain mental health conditions like obsessive-compulsive disorder, post-traumatic stress disorder, anxiety disorder, or dysthymia. These conditions might not exclude you from the study if they are not considered to be your main health concern.
Research Study Groups:
This trial has the following groups:- Group 1: Active rTMS treatment
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger